Meeting
2019 ASCO Annual Meeting
Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).
Authors
Claus Garbe
Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany
Claus Garbe , Tobias Sinnberg , Heike Niessner , Heiko Sülberg , Thomas K. Eigentler , Teresa Amaral
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9518)
DOI
10.1200/JCO.2019.37.15_suppl.9518
Abstract #
9518
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma.
First Author: Navneet Dhillon
Poster
2023 ASCO Annual Meeting
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
First Author: Maria Gonzalez
Poster
2022 ASCO Annual Meeting
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.
First Author: Tina J. Hieken
Poster
2022 ASCO Annual Meeting
Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).
First Author: Jose Lutzky